by Maria Zannes | Sep 3, 2025 | Press Releases
Noninvasive diagnostic can help federal medical system address veterans at higher risk for developing lung cancer SAN ANTONIO, TX – September 3, 2025 – U.S. Medicine, a leading publication for federal healthcare professionals, has featured bioAffinity Technologies’...
by Maria Zannes | Aug 29, 2025 | Articles, News
As published by US Medicine, the Voice of Federal Medicine by Mary Anne Dunkin | Aug 21, 2025 FORT SAM HOUSTON, TX — Lung cancer is the leading cause of cancer deaths in the United States. Early detection is vital, especially for veterans, who face a...
by Maria Zannes | Aug 18, 2025 | Press Releases
Financial and Clinical Leaders Provide Significant Expertise for the Company’s Commercial Growth SAN ANTONIO, Texas (August 18, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company advancing noninvasive diagnostics for the early...
by Maria Zannes | Aug 14, 2025 | Press Releases
SAN ANTONIO, Texas (August 14, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced the closing of its previously announced private...
by Maria Zannes | Aug 14, 2025 | Press Releases
CyPath® Lung revenues up 62% year-over-year in first six months of 2025 SAN ANTONIO, Texas (August 14, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung...
